# Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fed Conditions

> **NCT03947528** · PHASE1 · UNKNOWN · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 38 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Sarpogrelate HCL 300mg

## Key facts

- **NCT ID:** NCT03947528
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-04
- **Primary completion:** 2019-05-13
- **Final completion:** 2019-05-13
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2019-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03947528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03947528, "Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fed Conditions". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03947528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*